© 2022 MJH Life Sciences and Cancer Network. All rights reserved.
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
December 24, 2021
Experts in the multiple myeloma field discuss which front-line therapy is best for patients who are treatment ineligible.
October 21, 2021
After reviewing implications of the MAIA study in multiple myeloma, experts consider unmet needs and future directions in care.
Panelists discuss the case of a 77-year-old man with newly diagnosed multiple myeloma who wishes to discontinue therapy after achieving a very good partial response.
October 14, 2021
Experts review the case of a 75-year-old woman with newly diagnosed multiple myeloma and discuss treatment selection, continuation, reduction, and duration.
In-depth considerations for available frontline therapy regimens for patients with transplant-ineligible multiple myeloma.
October 07, 2021
A panel of experts reflects on appropriate actions to take after a patient achieves adequate response to therapy for transplant-ineligible multiple myeloma.
Shared insight on how best to assess a patient’s response to therapy for transplant-ineligible multiple myeloma.
September 30, 2021
Panelists elucidate how to determine transplant ineligibility and the goals of therapy while managing a patient with multiple myeloma.
Shared insight on the difficulties of transplant-ineligible newly diagnosed multiple myeloma and how to optimally approach treatment.